MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Incyte Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

58.61 0.26

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

57.77

Max

59.02

Pagrindiniai rodikliai

By Trading Economics

Pajamos

95M

201M

Pardavimai

39M

1.2B

P/E

Sektoriaus vid.

378.667

57.333

Pelnas, tenkantis vienai akcijai

1.43

Pelno marža

17.071

Darbuotojai

2,617

EBITDA

145M

337M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+25.27% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-5.4B

11B

Ankstesnė atidarymo kaina

58.35

Ankstesnė uždarymo kaina

58.61

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Incyte Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-24 23:54; UTC

Karštos akcijos

Stocks to Watch: Alphabet, Intel, AppFolio

2025-04-24 23:51; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

2025-04-24 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-04-24 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

2025-04-24 23:37; UTC

Svarbiausios naujienos

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

2025-04-24 23:36; UTC

Svarbiausios naujienos

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

2025-04-24 23:13; UTC

Svarbiausios naujienos
Uždarbis

Google's Earnings Power Holds Up in Global Turbulence -- Update

2025-04-24 23:09; UTC

Svarbiausios naujienos

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

2025-04-24 23:02; UTC

Įsigijimai, susijungimai, perėmimai

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

2025-04-24 23:02; UTC

Įsigijimai, susijungimai, perėmimai

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

2025-04-24 22:51; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

2025-04-24 22:48; UTC

Svarbiausios naujienos

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

2025-04-24 22:47; UTC

Rinkos pokalbiai

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

2025-04-24 22:38; UTC

Rinkos pokalbiai
Uždarbis

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

2025-04-24 22:24; UTC

Uždarbis

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

2025-04-24 22:24; UTC

Uždarbis

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

2025-04-24 22:24; UTC

Rinkos pokalbiai
Uždarbis

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

2025-04-24 22:23; UTC

Uždarbis

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

2025-04-24 22:11; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-04-24 22:11; UTC

Rinkos pokalbiai
Uždarbis

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

2025-04-24 22:09; UTC

Svarbiausios naujienos
Uždarbis

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

2025-04-24 22:00; UTC

Rinkos pokalbiai
Uždarbis

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

2025-04-24 21:39; UTC

Svarbiausios naujienos

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

2025-04-24 21:24; UTC

Svarbiausios naujienos
Uždarbis

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

2025-04-24 21:24; UTC

Svarbiausios naujienos
Uždarbis

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

2025-04-24 21:23; UTC

Svarbiausios naujienos
Uždarbis

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

2025-04-24 21:04; UTC

Uždarbis

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

2025-04-24 21:03; UTC

Uždarbis

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

2025-04-24 21:03; UTC

Uždarbis

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

2025-04-24 21:02; UTC

Uždarbis

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Akcijų palyginimas

Kainos pokytis

Incyte Corp Prognozė

Kainos tikslas

By TipRanks

25.27% į viršų

12 mėnesių prognozė

Vidutinis 73.87 USD  25.27%

Aukščiausias 92 USD

Žemiausias 52 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Incyte Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

18 ratings

6

Pirkti

11

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

58.33 / 59.22Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation